Division of Drug Informatics, School of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashiōsaka City, Osaka, 577-8502, Japan.
Sci Rep. 2023 Jul 19;13(1):11677. doi: 10.1038/s41598-023-38957-2.
The association between statins and open-angle glaucoma (OAG) remains controversial. This study investigated the relationship between statins and OAG in Japanese patients with dyslipidemia using the Japanese administrative claims database. A nested case-control study using two models was conducted using the JMDC claims database (01/2005-01/2020). The onset of OAG: index date was defined as the diagnosis of glaucoma, prescription of anti-glaucoma drugs, or surgery of glaucoma. For each case, a maximum of 10 age-, sex-, and calendar year/month-matched controls were randomly selected by risk-set sampling with replacement. The number of statin prescriptions during the exposure assessment period, which was identified as the 12-month (model 1) or 24-month (model 2) periods prior to the index date, was used as an indicator for statin exposure. Adjusted odds ratios (aORs) and 95% confidence interval (CI) were estimated using conditional logistic regression analyses. We identified 375,373 patients with newly diagnosed dyslipidemia. Of these, 6180 cases and 61,792 controls (model 1) and 4153 cases and 41,522 controls (model 2) were selected. Statin use was not identified as a significant risk factor for OAG (model 1: aOR 0.98, 95% CI 0.93-1.03, model 2: aOR 0.97, 95% CI 0.91-1.04). Compared with nonexposure, short-term exposure (< 2 years) to statins was not related to an increased risk of OAG in the Japanese working-age population with dyslipidemia.
他汀类药物与开角型青光眼(OAG)之间的关系仍存在争议。本研究使用日本行政索赔数据库调查了日本血脂异常患者中他汀类药物与 OAG 之间的关系。使用 JMDC 索赔数据库(2005 年 1 月至 2020 年 1 月)进行了嵌套病例对照研究,采用了两种模型。OAG 的发病:索引日期定义为青光眼的诊断、抗青光眼药物的处方或青光眼的手术。对于每个病例,通过风险集抽样和替换最多随机选择 10 名年龄、性别和日历年月匹配的对照。暴露评估期内他汀类药物处方的数量(模型 1 为索引日期前 12 个月,模型 2 为 24 个月)被用作他汀类药物暴露的指标。使用条件逻辑回归分析估计调整后的优势比(aOR)和 95%置信区间(CI)。我们确定了 375,373 例新诊断为血脂异常的患者。其中,6180 例病例和 61,792 例对照(模型 1)和 4153 例病例和 41,522 例对照(模型 2)被选中。他汀类药物的使用未被确定为 OAG 的显著危险因素(模型 1:aOR 0.98,95%CI 0.93-1.03,模型 2:aOR 0.97,95%CI 0.91-1.04)。与未暴露相比,在日本血脂异常的工作年龄人群中,短期(<2 年)暴露于他汀类药物与 OAG 风险增加无关。